Recombinant Human CD169/SIGLEC1, N-His

Description of Recombinant Human CD169/SIGLEC1, N-His

Introduction

Recombinant Human CD169/SIGLEC1 is a type I transmembrane protein that belongs to the sialic acid-binding Ig-like lectin (SIGLEC) family. It is also known as Sialoadhesin (Sn) and is encoded by the SIGLEC1 gene. CD169 is a cell surface receptor that is primarily expressed on macrophages and dendritic cells in the immune system. It has been shown to play a critical role in the recognition and clearance of pathogens, as well as in the regulation of immune responses.

Structure of Recombinant Human CD169/SIGLEC1

The recombinant form of CD169 is a glycosylated protein with a molecular weight of approximately 200 kDa. It is composed of an extracellular domain, a transmembrane region, and a cytoplasmic tail. The extracellular domain contains nine Ig-like domains, including a sialic acid-binding domain, which is responsible for the binding of CD169 to its ligands. The transmembrane region anchors the protein to the cell membrane, while the cytoplasmic tail contains signaling motifs that are important for the activation of downstream signaling pathways.

Activity of Recombinant Human CD169/SIGLEC1

CD169 is primarily known for its role in the recognition and uptake of pathogens by macrophages and dendritic cells. This is achieved through its ability to bind to sialylated glycans on the surface of pathogens, such as viruses and bacteria. This binding triggers the internalization of the pathogen into the cell, where it can be degraded and presented to other immune cells for recognition.

In addition to its role in pathogen recognition, CD169 has also been shown to play a role in the regulation of immune responses. It has been reported to act as a negative regulator of T cell activation by inducing the production of the anti-inflammatory cytokine IL-10. CD169 has also been shown to play a role in the maintenance of immune tolerance by promoting the development of regulatory T cells.

Application of Recombinant Human CD169/SIGLEC1

The recombinant form of CD169 has been widely used in research and clinical applications. One of its main applications is in the study of immune responses to pathogens. The ability of CD169 to bind to sialylated glycans on pathogens makes it a valuable tool for the isolation and characterization of these pathogens from complex samples.

Furthermore, the recombinant form of CD169 has also been used in the development of therapeutic strategies for the treatment of infectious diseases. By targeting CD169 on immune cells, researchers have been able to enhance the clearance of pathogens and improve immune responses.

Another potential application of recombinant CD169 is in the development of vaccines. By incorporating sialylated glycans into vaccine formulations, it is possible to target CD169 on immune cells and enhance the uptake and presentation of vaccine antigens, leading to a more robust immune response.

Conclusion

In summary, recombinant human CD169/SIGLEC1 is a glycosylated protein that plays a critical role in the recognition and clearance of pathogens, as well as in the regulation of immune responses. Its unique structure and activity make it a valuable tool in research and clinical applications, particularly in the study and treatment of infectious diseases. With ongoing research and development, the potential applications of recombinant CD169 are likely to expand, making it an important protein in the field of immunology.